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Background: Antimicrobial resistance (AMR) is one of the major threats to public health around the world. Besides
the intense use and misuse of antimicrobial agents as the major force behind the increase in antimicrobial
resistance, the exponential increase of international travel may also substantially contribute to the emergence and
spread of AMR. However, knowledge on the extent to which international travel contributes to this is still limited.
The Carriage Of Multiresistant Bacteria After Travel (COMBAT) study aims to 1. determine the acquisition rate of
multiresistant Enterobacteriaceae during foreign travel 2. ascertain the duration of carriage of these micro-organisms 3.
determine the transmission rate within households 4. identify risk factors for acquisition, persistence of carriage and
transmission of multiresistant Enterobacteriaceae.
Methods/design: The COMBAT-study is a large-scale multicenter longitudinal cohort study among travellers
(n = 2001) and their non-travelling household members (n = 215). Faecal samples are collected before and
immediately after travel and 1 month after return from all participants. Follow-up faecal samples are collected
3, 6 and 12 months after return from travellers (and their non-travelling household members) who acquired
multiresistant Enterobacteriaceae. Questionnaires are collected from all participants at each time-point. Faecal samples
are screened phenotypically for the presence of extended-spectrum beta-lactamase (ESBL) or carbapenemase-producing
Enterobacteriaceae. Positive post-travel isolates from travellers with negative pre-travel samples are genotypically
analysed for ESBL and carbapenemase genes with microarray and gene sequencing.
Discussion: The design and scale of the COMBAT-study will enable us to provide much needed detailed insights into
the risks and dynamics of introduction and spread of ESBL- and carbapenemase-producing Enterobacteriaceae by
healthy travellers and the potential need and measures to monitor or manage these risks.
Trial registration: The study is registered at clinicaltrials.gov under accession number NCT01676974.
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The problem of antimicrobial resistance (AMR) is
worldwide one of the foremost health issues that we face
in the coming decades [1]. Bacterial AMR reduces clinical
efficacy and increases treatment costs. Furthermore, AMR
jeopardizes the achievements of modern medicine, since
the success of interventions such as organ transplantation,
cancer chemotherapy and major surgery depends on
effective antimicrobial agents for prevention and treatment
of infections. With a dearth of novel antibiotics in the
pipeline, the conservation of existing ones is imperative [2].
Next to the well-established role of (inappropriate)
antimicrobial use in humans and animals, the exponential
increase of international travel may substantially contribute
to the emergence and spread of AMR since it allows
resistant bacteria or bacterial mobile gene elements
carrying resistance genes (e.g. plasmids) to be rapidly
transported between regions [3]. To what extent foreign
travel poses a risk for the acquisition of AMR remains,
however, largely unknown, as the presence of resistant
bacteria in the normal human microbiota following travel
usually remains undetected unless they cause manifest
infection and disease. Yet, due to the high likelihood of
contact and genetic exchange with potential pathogens,
the human microbiota warrants special attention as
perhaps the most accessible reservoir of resistance genes.
Besides being part of the normal human micro-
biota, Enterobacteriaceae are also important causes of
community-acquired and nosocomial infections. Entero-
bacteriaceae can acquire resistance genes through horizon-
tal gene transfer. Genes encoding for resistance to different
classes of antibiotics, such as beta-lactams, quinolones and
aminoglycosides are often located on plasmids. Multiple
genes, each encoding for resistance to different classes of
antibiotics, can be found on the same plasmid [4]. Selective
pressure of one antibiotic can therefore lead to resistance
to several classes of antibiotics.
Plasmid borne resistance to beta-lactam antibiotics
in Enterobacteriaceae is emerging worldwide, due to
the production of enzymes called extended-spectrum
beta-lactamases (ESBLs). ESBLs have broad-spectrum
activity against penicillins, cephalosporins and monobac-
tams by hydrolyzing the beta-lactam ring of these anti-
biotics, leading to inactivation. Even more worrisome,
Enterobacteriaceae can acquire resistance genes encoding
for enzymes called carbapenemases. These carbapenemase-
producing Enterobacteriaceae (CPE’s) are “extreme drug
resistant”. Their enzymes are active against our last resort
class of antibiotics: the carbapenems. Up to now, only
case-reports have shown acquisition or infection with
CPE’s among travellers upon visit or hospitalization in
endemic areas [5].
Besides horizontal gene transfer, AMR bacteria can
spread from the traveller to other family members andbeyond, through the faeco-oral route [6]. The traveller
can therefore be seen as an interactive biological unit
who picks up, processes, carries and drops off microbial
genetic material [7]. Consequently, local emergence of
AMR can rapidly result in worldwide spread.
So far, five small to medium-sized prospective studies
(n = 40–370) have investigated acquisition of AMR
Enterobacteriaceae during international travel. These
studies reported acquisition rates of ESBL-producing
Enterobacteriaceae (ESBL-E) in faeces ranging from 24%
to 33% among Swedish, Australian, American and Dutch
travellers, with acquisition rates up to 88% depending
on destination [8-12]. No acquisition of carbapenemase-
producing Enterobacteriaceae was found.
In an earlier prospective study among travellers, a
rapid decline in carriage of resistant isolates was demon-
strated. A relative small proportion (10%) of subjects
had persistent carriage after 6 months [13].
While these studies identified international travel as an
important risk factor for acquiring AMR microorganisms,
several important questions still need to be fully addressed
to understand the contribution of travel to AMR emer-
gence and spread, to assess the risk for public health and
to identify measures to manage this risk. These knowledge
gaps include (1) identification of travel-associated risk fac-
tors (including destination) for acquisition and subsequent
carriage of these resistant microorganisms, (2) duration of
colonization with AMR strains acquired during travel, (3)
probability and dynamics of subsequent transmission of
AMR strains within households and (4) the proportion of
colonized travellers who develop infections with these re-
sistant bacteria.
Scope of research
The Carriage Of Multiresistant Bacteria After Travel
(COMBAT) Study, aims to prospectively study the
influence of international travel and travel-associated risk
factors on the acquisition, persistence and transmission of
AMR in the endogenous microbiota of healthy individuals.
The specific aims are:
1. to determine the acquisition rate of ESBL- and
carbapenemase-producing Enterobacteriaceae during
foreign travel by comparing pre- and post-travel
faecal samples;
2. to ascertain the duration of carriage of these
microorganisms (or their resistance genes/mobile
genetic elements) by studying faecal specimens at
regular intervals up to 1 year after return;
3. to mathematically model the decolonization
and transmission rates of these imported
Enterobacteriaceae (or their resistance genes/mobile
elements) within households by prospectively
studying consecutive specimens from household
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his/her travel);
4. to identify the risk factors for acquisition, persistence
of carriage and transmission of ESBL- and
carbapenemase-producing Enterobacteriaceae;
5. to examine whether carriers of resistant
Enterobacteriaceae have a higher risk of bacterial
infections in the year after travel (compared to
non-carriers).
Methods/design
Design
The design of the COMBAT-study is a multicenter lon-
gitudinal cohort study among travellers who are followed
from one week prior to travel departure until 12 months
after return. In order to study household transmission,
non-travelling household members are also included and
are followed over the same period as their travelling
household members. Figure 1 depicts a flowchart of the
study design and procedures.
Study area and recruiting centers
Participants are recruited at the outpatient clinics run by the
Academic Medical Center (Amsterdam, the Netherlands),
Havenziekenhuis (Rotterdam, the Netherlands) and
Maastricht University Medical Center/Public Health
Service South Limburg (Maastricht, the Netherlands),
which together are visited by approximately 52.700
travellers each year for travel advice and vaccinations.
Subjects are recruited within a period of one year, from
November 2012 until November 2013.
Eligibility criteria
Travellers - Eligible subjects are adult (≥18 years) volunteers
visiting one of the above stated travel clinics, travelling
abroad for a minimum of one week to a maximum of three
months. Minors (<18 years) and incapacitated subjects are
excluded from this study.
Non-travelling household members–Non-travelling adult
household members of participating travellers are also
enrolled. A household contact is defined as an individ-
ual who lives in the same house as the traveller and
shares the same kitchen and/or bathroom and/or toi-
let on a regular basis.
Sample size and power calculation
In order to determine the minimum number of trav-
ellers required to detect risk factors for acquisition of
ESBL-producing Enterobacteriaceae with sufficient
power, the following assumptions were made: 1. a 2%
pre-travel prevalence of carriage of ESBL-producing
Enterobacteriaceae; 2. an acquisition rate of ESBL-producing
Enterobacteriaceae of 24% during travel; 3. a two-
sided significance level (alpha) of 0.05; 4. a power (1-beta)of 80%; 5. a minimum odds ratio of 2.0; 6. a minimum
prevalence of a travel-associated risk factor of 5%. Based
upon these assumptions a sample size of 1541 analyzable
subjects is required. Accounting for an estimated attrition
rate of 20% immediately after travel (t = 1), a total of 1926
travellers need to be recruited.
After one year of follow-up, 2001 travellers were in-
cluded fulfilling the requested sample size. To minimize
the drop-out and non-response levels, participants are
reminded through several channels in case question-
naires or samples are not received in time. Participants
are sent reminders initially by emails, followed by text
messages to their mobile phones and, in case of no re-
sponses are received, are finally contacted by telephone
by one of the researchers. This resulted in an attrition
rate immediately after travel (t = 1) of 1,6%, being far
lower than expected. Table 1 shows minimal effect sizes
that can be detected within the final cohort according to
a prevalence of a risk factor ranging from 5 to 50%.
Study procedures
Eligibility screening activities
All clerks of the participating outpatient travel clinics
are instructed to hand out an information flyer on the
COMBAT-study to all travellers visiting the clinics
during the recruitment period. If travellers are interested
to participate they are instructed to fill in the flyer with
their contact details, date of departure and return, and
number of non-travelling household members. Travellers
who meet the eligible criteria are provided with additional
information on the study procedure and subsequently con-
tacted by phone to confirm their willingness to participate.
Travellers not fulfilling the eligible criteria receive an email
informing them on the reason for exclusion.
Ethical approval and informed consent
Subjects willing to participate are subsequently sent
written information on the study procedures along
with an informed consent form. Only participants pro-
viding written informed consent are enrolled. Ethical
approval was obtained by the Medical Ethical Committee
of Maastricht University Medical Center (study number:
METC 12-4-093).
Data collection
Faecal sampling
Travellers and if applicable their participating non-
travelling household members are instructed to self-collect
a faecal sample before travel (t = 0) as well as immediately
(t = 1) and one month (t = 2) after return. In case any
of these samples from a traveller or his/her household
member(s) is positive for ESBL- or carbapenemase-
producing Enterobacteriaceae, both the traveller and the
household member(s) are asked to provide additional
Table 1 Effect sizes that minimally can be detected
according to the prevalence of the exposure in the final
cohort of 2001 travellers
Proportion exposed (%) Odds ratio
50% 1.36
25% 1.41
10% 1.64
5% 1.92
Figure 1 Flowchart of study design. * Depending on colonization status of traveller (or his/her household member) at previous time-points.
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12 months after travel, t = 3-5). Sample collection and
shipment kits are sent to participants before travel (for the
collection of samples at t = 0 and t = 1), 2 weeks prior
to the subsequent follow-up timepoint (t = 2) and if
applicable 2 weeks prior to each of the follow-up time
points (t = 3-5). A sample collection and shipment kit con-
sists of an instruction form, a safety bag, a bibulous tissue,
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swab with modified Cary Blair transport medium (Fecal
Swab®; Copan, Brescia, Italy). Participants are instructed to
sample fresh stools by turning the swab into faeces with-
out touching the toilet or water, package the sample ac-
cording to the instructions and send to the laboratory
immediately.
At the laboratory, samples are processed upon arrival.
Residuals are aliquoted and stored at −80°C for future
research.
Questionnaires
Questionnaires (in Dutch language) are sent to all partici-
pants at each timepoint. (t = 0-5). All questionnaires collect
information on the date of sample collection and gastro-
intestinal symptoms, including the ROME III IBS diagnos-
tic questionnaire [14]. The pre-travel questionnaire (t = 0)
comprises detailed information on demographic parame-
ters (e.g. ethnicity, gender, age, household composition),
travel history in the past years, pre-existing morbidity and
medication use, hospital admissions and antibiotic use
during the past year, as well as dietary preferences. The
first post-travel questionnaire (t = 1) mainly collects infor-
mation on travel details, such as duration; destination(s);
urban/rural travel; type of travel (e.g. business, family visit,
holiday); lodging (e.g. hotel, tent, family, locals); ailments
or illnesses during travel (i.e. gastroenteritis); hospital
admission; medical interventions and use of medication
(in particular antibiotic use); place of meal consumption
(e.g. at hotel, local restaurants, food stalls); unboiled/
unbottled water consumption. The questionnaires at each
subsequent follow-up collect data on intercurrent
travel, medication use (including antibiotic use), hospital
admissions and occurrence of illnesses/infections.Table 2 Baseline characteristics of travellers and non-travellin
Rotterdam Amsterdam
Travellers Household
members
Travellers Househo
membe
(n = 1110) (n = 129) (n = 496) (n = 43)
Sex
Male 541 (48.7%) 39 (30.2%) 208 (41.9%) 18 (41.9
Female 569 (51.3%) 90 (69.8%) 288 (58.1%) 25 (58.1
Age in years
(median, range)
52.0 (18.1-81.7) 46.3 (18.4-82.0) 44.7 (19.8-74.6) 41.1 (18
Continents visited
by traveller
Asia 557 (50.2%) 259 (52.2%)
Africa 362 (32.6%) 148 (29.8%)
America 177 (15.9%) 81 (16.3%)
Europe 11 (1.0%) 6 (1.2%)
Oceania 3 (0.3%) 2 (0.4%)If applicable, travellers are asked to provide data on
their relationship to the household members who also
participate in the study. This includes data on the type
of relationship (roommate, partner, parent, child, sibling,
other), forms of contact (e.g. sharing of bed, towel,
toothbrush, balms/lotions) and on household characteris-
tics (e.g. household size). Participating non-travelling
household members also receive questionnaires at each
timepoint (t = 0-5) on demographic parameters, travel
history, travel during the study period, medication use,
hospital admission and occurrences of illness/infections.
Microbiological methods
Bacterial culture and antibiotic susceptibility testing
Faecal samples are processed immediately upon arrival
at the laboratory. The samples are selectively enriched:
100 microliter of the liquid medium with faeces is pipetted
into 5 ml of tryptic soy broth (TSB) supplemented with
vancomycine (50 mg/l), followed by overnight incubation
at 35°C [15]. The next day, volumes of 10 microliters are
inoculated on chromID® ESBL (bioMérieux, Marcy l’Etoile,
France), a selective agar plate to screen for ESBL- and
carbapenemase-producing Enterobacteriaceae. These agar
plates are incubated overnight at 35°C. All colonies
growing on chromID® ESBL agar are further characterized
to the species level using MALDI-TOF (Bruker, London,
United Kingdom). Minimum inhibitory concentrations
(MIC) are measured for all Enterobacteriaceae by the use
of the automated susceptibility testing system Vitek 2
(bioMérieux, Marcy l’Etoile, France). The susceptibility
testing results are interpreted by the clinical breakpoints
recommended by EUCAST (the European Committee
on Antimicrobial Susceptibility Testing). Phenotypic
confirmation of ESBL-producing Enterobacteriaceae isg household members according to study center
Maastricht Total
ld
rs
Travellers Household
members
Travellers Household
members
(n = 395) (n = 43) (n = 2001) (n = 215)
%) 171 (43.3%) 23 (53.5%) 920 (46.0%) 80 (37.2%)
%) 224 (56.7%) 20 (46.5%) 1081 (54.0%) 135 (62.8%)
.9-78.0) 50.4 (18.2-71.9) 50.6 (18.4-71.6) 50.5 (18.1-81.7) 46.9 (18.4-82.0)
200 (50.6%) 1016 (50.8%)
123 (31.1%) 633 (31.6%)
68 (17.2%) 326 (16.3%)
4 (1.0%) 21 (1.0%)
0 (0.0%) 5 (0.2%)
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to current national Dutch guidelines. Enterobacteriaceae
with an MIC for imipenem and/or meropenem above the
recommended screening breakpoint(s) measured by the
Vitek 2 will be confirmed by Etest (bioMérieux, Marcy
l’Etoile, France) [16].
Genotypic characterization
ESBL- and carbapenemase-producing post-travel iso-
lates (t = 1) from travellers with negative pre-travel
samples (t = 0) are screened for the presence of multiple
classes of ESBL and carbapenemase genes using micro-
array (Identibac® AMR08; Alere Technologies GmbH,
Jena, Germany). This platform is a miniaturized DNA-
hybridization array in a strip based system for the detection
of >120 antimicrobial resistance genes in Gram-negative
bacteria, including those conferring resistance to ami-
noglycosides, trimethoprim, sulphonamides, tetracy-
clines, quinolones, and beta-lactams, including ESBLs
and carbapenemases. In case of positive microarray
signals, targeted PCR and DNA sequencing will be used
to further genetically characterize the specific type
of ESBL or carbapenemase in t = 1 isolates. DNAFigure 2 Geographic distribution of residences of participating travel
center. i. Yellow circles represent participants from Tropencentrum AMC, A
Havenziekenhuis, Rotterdam. iii. Blue circles represent participants from Masequences will be analyzed using existing DNA databases
(NCBI GenBank and Lahey beta-lactamase classifica-
tion and amino acid sequences for TEM, SHV and OXA-
Extended-Spectrum and Inhibitor Resistant Enzymes)
which are updated regularly.
In case of negative microarray results of phenotyp-
ically resistant isolates, additional screening will be
performed by PCR. To confirm persistence of colonization
and/or transmission, phenotypically confirmed ESBL- or
carbapenemase-producing isolates from follow-up sam-
ples of travellers and household members will be tested by
targeted PCR and DNA sequencing (based on results from
t = 1). Clonal bacterial spread within households will be
confirmed or excluded by molecular (plasmid-) typing.
Results
2001 travellers and 215 non-travelling household members
were included. The median age of travellers and household
members is respectively 50.5 years (range 18.1-81.7) and
46.9 years (range 18.4-82.0), 54.0% of travellers and 62.8%
of household members are female (center-specific charac-
teristics are presented in Table 2). The distribution of the
participants throughout the Netherlands and across studylers (n = 2001) throughout the Netherlands according to study
msterdam. ii. Red circles represent participants from Travel Clinic
astricht University Medical Center, Maastricht.
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visited were South-Eastern Asia, Eastern Africa, Southern
Asia and South America (Figure 3).
Discussion
The design and scale of the COMBAT-study are optimal
to study the influence of international travel and travel-
associated risk factors on the acquisition, persistence of
carriage and transmission of AMR Enterobacteriaceae. A
limited number of previous studies have suggested high
acquisition rates of AMR Enterobacteriaceae during
international travel, but most did not examine the
duration of colonization and none looked at local
transmission of imported AMR. Our larger scale lon-
gitudinal studies will not only assess the probability
of colonization by AMR Enterobacteriaceae during
international travel along with associated risk factors, but
will also determine the duration of such colonization as
well as the probability and dynamics of subsequent
transmission of AMR within households. In addition,
while the main focus of the project will be on ESBL- and
carbapenemase-producing Enterobacteriaceae, innovativeFigure 3 Heatmap showing the countries visited by the participating
country. ii. Light yellow color indicates 2–10 travellers visited country. iii. Or
color indicates 50–100 travellers visited country. v. Dark brown color indicamolecular approaches (microarray) will be used to provide
a more comprehensive and complete picture of associated
resistance genes acquired during travel. Our extensive
data from questionnaires will identify travel-associated
risk factors for acquisition, persistence and transmission
of AMR Enterobacteriaceae.
Selection towards a more affluent and healthy study
population is a common phenomenon in epidemiological
studies and has likely also occurred in our study. This
potential selection may be related to some determinants
and outcomes separately (non-differential selection),
affecting the frequency rates and, as a consequence,
the statistical power and generalizability of the results
[17]. However, since we have access to the demographic
data of all visitors of the travel clinics during the re-
cruitment period, we will be able to perform detailed
non-response analysis and examine to what extent the
study population deviates from its source population. The
incidence rates of AMR acquisition found in the
study will be interpreted accordingly. Moreover, this
selection would only lead to bias in etiological associ-
ation studies if the selection mechanisms are relatedtravellers (n = 2001). i. Grey color indicates 0–1 travellers visited
ange color indicates 11–51 travellers visited country. iv. Light brown
tes > 100 travellers visited country.
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selection), which is, in contrast to retrospective and
cross-sectional studies, unlikely in the present prospective
study.
Major efforts have been made to keep the follow-up
rates as high as possible and to prevent (selective) loss
to follow-up. This has resulted in follow-up rates as high
as 98.4% immediately after travel (t = 1). Taken together,
results from this study will provide much needed detailed
insights into the risks and dynamics of introduction and
spread of AMR by healthy travellers and the potential
need and measures to monitor or manage these risks.
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